Trial Profile

A phase 1 clinical study of a selective HDAC6 inhibitor (SP-2-225)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 05 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SP 2 225 (Primary)
Indications Breast cancer; Lung cancer; Malignant melanoma; Multiple myeloma
Focus Adverse reactions

Most Recent Events

05 Apr 2023 New trial record
22 Mar 2023 According to a Shuttle Pharmaceuticals media release, goal of company is to submit an investigational new drug application (IND) for their IND-enabling studies for selective HDAC6 inhibitor and initiation of a Phase I clinical trial in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com